Recent

% | $
Quotes you view appear here for quick access.

DexCom, Inc. (DXCM) Message Board

cblount83 2 posts  |  Last Activity: Dec 22, 2015 7:18 PM Member since: Jan 12, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • cblount83 cblount83 Dec 22, 2015 7:18 PM Flag

    I also agree with this post. Some people are tainted because the company made mistakes getting to this point but thats in the past and has nothing to do with the future with the drugs approved.

  • Reply to

    The FV floor is $5.50 for AEZS

    by knoxville_rider33 Dec 22, 2015 6:10 PM
    cblount83 cblount83 Dec 22, 2015 7:17 PM Flag

    I agree that the floor should be between $5 - $6 bucks based on their big cash position. The tougher part is valuing the drugs in development. I've looked at Macrilen and if you consider the market size and assume Aeterna can get 1/3 market share for AGHD then the drug should be worth another $22-$29 a share in the first year of approval and could grow from there. But there is still risk for FDA approval so you have to discount that down. Zop-Dox in phase 3 is tougher to value imo but should be worth at least another $9 a share, The trial shows that recruiting is done so it is moving toward completion by next year. Zop-Dox for ovarian indication is only in phase 2 so it probably isnt really a value contributor unless it gets to phase 3. All in all AEZS could see $20 in 2016 with only 10 million shares outstanding.

DXCM
61.98-8.65(-12.25%)Feb 5 4:00 PMEST